Mainstay Prepares For CE Mark And European Launch Of Flagship Back-Pain Device
This article was originally published in Clinica
Executive Summary
Mainstay Medical expects the results of the ReActiv8-A trial to soon support a CE Mark for the ReActiv8 implantable stimulation system, allowing the Dublin-based company to launch the device in Europe beginning in Germany.